GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Additional Paid-In Capital

Helix BioPharma (TSX:HBP) Additional Paid-In Capital : C$46.83 Mil(As of Oct. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Additional Paid-In Capital?


Helix BioPharma's quarterly additional paid-in capital increased from Apr. 2024 (C$46.56 Mil) to Jul. 2024 (C$47.36 Mil) but then stayed the same from Jul. 2024 (C$47.36 Mil) to Oct. 2024 (C$46.83 Mil).

Helix BioPharma's annual additional paid-in capital increased from Jul. 2022 (C$37.59 Mil) to Jul. 2023 (C$44.14 Mil) and increased from Jul. 2023 (C$44.14 Mil) to Jul. 2024 (C$47.36 Mil).

Helix BioPharma Additional Paid-In Capital Historical Data

The historical data trend for Helix BioPharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Additional Paid-In Capital Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.54 27.87 37.59 44.14 47.36

Helix BioPharma Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.81 46.07 46.56 47.36 46.83

Helix BioPharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Helix BioPharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Additional Paid-In Capital
Comparable Companies
TSXV:NRX TSX:MBX XCNQ:GLAB NEOE:BMND TSX:BCT XCNQ:DTC TSXV:MIR TSXV:GSD TSXV:TTI XCNQ:DOSE VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
HBPCF:USA HBP0:Germany
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Website
https://www.helixbiopharma.com
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.